

Financial Report Fiscal 2023 Supplementary Materials

HOGY MEDICAL Co., Ltd.

April 15,2024

Table of Contents

Consolidated Basis

Fiscal 2023 Statements of Income	• • • • • • •	1 P
Fiscal 2023 Statements of Income by Quarter	• • • • • • • • • • • • • • • • • • • •	2 P
Fiscal 2024 Projected Statements of Income	• • • • • • • •	3 P
Fiscal 2023 Sales Results by Product Line	• • • • • • •	4 P
Fiscal 2024 Sales Plan by Product Line	• • • • • • • •	5 P
SG&A (Actual and Forecast)	• • • • • • • •	6 P
Other Income/Expenses (Actual and Forecast)		
Capital Expenditures and Depreciation Expenses	• • • • • • • •	7 P
Balance Sheets (Major Changes)		8 P

Non-Consolidated Basis

Fiscal 2023	Statements of Income	9 P
Fiscal 2023	Statements of Income by Half	10 P
Fiscal 2024	Projected Statements of Income	······ 11 P
Total Manuf	acturing Costs	····· 12 P

(Notes Concerning Forward-Looking Statements)

Projections throughout these materials are provided as a reference for investors. They are based on estimates and forecasts, and shall not be regarded as pledges or guarantees. They shall be used on the full acknowledgment that actual results may naturally differ from projections.

First Quarter

¥ millions, rounded down

	June 2023 Results		June 2022 Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	%
Net sales	9,679	100.0	9,447	100.0	231	102.5
Cost of Sales	6,083	62.9	5,357	56.7	726	113.6
Gross profit	3,595	37.1	4,090	43.3	-494	87.9
SG&A expenses	2,293	23.7	2,232	23.6	61	102.7
Operating income	1,302	13.5	1,857	19.7	-555	70.1
Other income	123		31		91	
Other expenses	195		46		149	
Ordinary income	1,230	12.7	1,843	19.5	-613	66.7
Extraordinary income	-		-		-	
Extraordinary expenses	0		0		0	
Income before income taxes and minority interests	1,229	12.7	1,843	19.5	-613	66.7
Corporation tax, etc.	347		548		-201	
(Tax burden)	28.3%		29.8%			
Minority interests	-4		-9		5	
Profit attributable to owners of parent	886	9.2	1,304	13.8	-418	67.9
EPS (total shares)	¥35.08		¥39.91			
EPS (minus treasury shares)	¥36.53		¥53.77			

First Half Results

¥ millions, rounded down

	Sept. 2023 Interim Results		Sept. 2022 Interim Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	%
Net sales	19,536	100.0	19,201	100.0	335	101.7
Cost of Sales	12,597	64.5	11,483	59.8	1,113	109.7
Gross profit	6,938	35.5	7,717	40.2	-778	89.9
SG&A expenses	4,563	23.4	4,532	23.6	30	100.7
Operating income	2,375	12.2	3,185	16.6	-809	74.6
Other income	239		108		130	
Other expenses	241		131		110	
Ordinary income	2,373	12.1	3,162	16.5	-789	75.0
Extraordinary income	40		-		40	
Extraordinary expenses	0		0		0	
Income before income taxes and minority interests	2,413	12.4	3,162	16.5	-749	76.3
Corporation tax, etc.	689		950		-261	
(Tax burden)	28.6%		30.0%			
Minority interests	-8		-20		12	
Profit attributable to owners of parent	1,732	8.9	2,232	11.6	-500	77.6
EPS (total shares)	¥68.59		¥68.32			

 EPS (total shares)
 ¥68.59
 ¥68.32

 EPS (minus treasury shares)
 ¥71.40
 ¥92.05

 Number of shares outstanding
 25,256,963
 32,682,310

 Weighted-average number of shares outstanding (after deducting treasury shares)
 24,261,879
 24,257,064

Third Quarter

¥ millions, rounded down

	Dec. 2023		Dec. 2022		Year-on-Year	
	Interim Results		Interim Results		Comparison	
	Amount	% of total	Amount	% of total	Amount	%
Net sales	29,754	100.0	29,535	100.0	219	100.7
Cost of Sales	19,423	65.3	17,539	59.4	1,883	110.7
Gross profit	10,331	34.7	11,996	40.6	-1,664	86.1
SG&A expenses	6,844	23.0	6,932	23.5	-87	98.7
Operating income	3,487	11.7	5,064	17.1	-1,577	68.9
Other income	357		236		120	
Other expenses	256		74		182	
Ordinary income	3,587	12.1	5,226	17.7	-1,638	68.6
Extraordinary income	40		-		40	
Extraordinary expenses	10		0		10	
Income before income taxes and minority interests	3,617	12.2	5,226	17.7	-1,608	69.2
Corporation tax, etc.	1,019		1,543		-524	
(Tax burden)	28.2%		29.5%			
Minority interests	-11		-27		16	
Profit attributable to owners of parent	2,609	8.8	3,710	12.6	-1,101	70.3
EPS (total shares)	¥103.32		¥113.54			

 EPS (minus treasury shares)
 ¥107.54
 ¥152.97

 Number of shares outstanding
 25,256,963
 32,682,310

 Weighted-average number of shares outstanding (after deducting treasury shares)
 24,266,016
 24,257,041

Full-year

¥ millions, rounded down

ruli-yeai										ounaea aown
	Fiscal			2022		n-Year		2023	Revise	
	Res	ults	Res	ults	Comparison		Revised Plan		Comparison	
	Amount	% of total	Amount	% of total	Amount	%	Amount	% of total	Amount	%
Net sales	39,100	100.0	38,981	100.0	119	100.3	39,200	100.0	-99	99.7
Cost of Sales	26,037	66.6	23,241	59.6	2,795	112.0	26,080	66.5	-42	99.8
Gross profit	13,063	33.4	15,740	40.4	-2,676	83.0	13,120	33.5	-56	99.6
SG&A expenses	8,894	22.7	9,105	23.4	-211	97.7	9,080	23.2	-185	98.0
Operating income	4,169	10.7	6,634	17.0	-2,465	62.8	4,040	10.3	129	103.2
Other income	440		261		179		430		10	
Other expenses	363		242		121		420		-56	
Ordinary income	4,245	10.9	6,653	17.1	-2,408	63.8	4,050	10.3	195	104.8
Extraordinary income	40		-		40		40		0	
Extraordinary expenses	210		464		-254		200		10	
Income before income taxes and minority interests	4,075	10.4	6,189	15.9	-2,113	65.9	3,890	9.9	185	104.8
Corporation tax, etc.	1,282		1,904		-621		1,144		137	
(Tax burden)	31.5%		30.8%				29.4%			
Minority interests	-11		-31		20		-14		3	
Profit attributable to owners of parent	2,804	7.2	4,316	11.1	-1,511	65.0	2,760	7.0	44	101.6
EPS (total shares)	¥111.04		¥132.08			<u>-</u>	¥109.28			

EPS (cloid shares) #111.04 #152.06 #109.26 EPS (minus treasury shares) #115.57 #177.95 #113.73 Number of shares outstanding 25,256,963 32,682,310 25,256,963 Weighted-average number of shares outstanding (after deducting treasury shares) 24,268,040 24,257,024 24,268,040

Fiscal 2023

	First	Second	Third	Fourth
			7	
	Quarter	Quarter	Quarter	Quarter
Net sales	9,679	9,856	10,218	9,345
Cost of Sales	6,083	6,513	6,825	6,613
Gross profit	3,595	3,343	3,392	2,731
SG&A expenses	2,293	2,269	2,281	2,049
Operating income	1,302	1,073	1,111	682
Other income	123	116	118	82
Other expenses	195	46	15	107
Ordinary income	1,230	1,143	1,214	657
Extraordinary income	-	40	-	-
Extraordinary expenses	0	0	9	199
Income before income taxes and minority interests	1,229	1,183	1,204	458
Corporation tax, etc.	347	341	330	263
(Tax burden)	28.3%	28.8%	27.4%	57.4%
Minority interests	-4	-3	-3	0
Profit attributable to owners of parent	886	846	877	195

¥ millions, rounded down						
	Third Quarter					
First Half	(Cumulative)	Full-year				
19,536	29,754	39,100				
12,597	19,423	26,037				
6,938	10,331	13,063				
4,563	6,844	8,894				
2,375	3,487	4,169				
239	357	440				
241	256	363				
2,373	3,587	4,245				
40	40	40				
0	10	210				
2,413	3,617	4,075				
689	1,019	1,282				
28.6%	28.2%	31.5%				
-8	-11	-11				
1,732	2,609	2,804				

Fiscal 2022

¥	millions.	round	ed	dowr

	First	Second	Third	Fourth
	Quarter	Quarter	Quarter	Quarter
Net sales	9,447	9,753	10,334	9,445
Cost of Sales	5,357	6,126	6,055	5,702
Gross profit	4,090	3,627	4,278	3,743
SG&A expenses	2,232	2,300	2,399	2,173
Operating income	1,857	1,327	1,879	1,570
Other income	31	77	127	24
Other expenses	46	85	-57	167
Ordinary income	1,843	1,318	2,064	1,426
Extraordinary income	-	-	-	-
Extraordinary expenses	0	0	0	464
Income before income taxes and minority interests	1,843	1,318	2,063	962
Corporation tax, etc.	548	401	593	360
(Tax burden)	29.8%	30.4%	28.8%	37.4%
Minority interests	-9	-10	-7	-3
Profit attributable to owners of parent	1,304	928	1,477	605

+ minoris, rounded down							
	Third Quarter						
First Half	(Cumulative)	Full-year					
19,201	29,535	38,981					
11,483	17,539	23,241					
7,717	11,996	15,740					
4,532	6,932	9,105					
3,185	5,064	6,634					
108	236	261					
131	74	242					
3,162	5,226	6,653					
-	-	-					
0	0	464					
3,162	5,226	6,189					
950	1,543	1,904					
30.0%	29.5%	30.8%					
-20	-27	-31					
2,232	3,710	4,316					

Change(Amount)

¥ millions, rounded down

	First	Second	Third	Fourth
	Quarter	Quarter	Quarter	Quarter
Net sales	231	103	-115	-100
Cost of Sales	726	387	770	911
Gross profit	-494	-284	-886	-1,011
SG&A expenses	61	-30	-118	-123
Operating income	-555	-253	-767	-887
Other income	91	39	-9	58
Other expenses	149	-39	72	-60
Ordinary income	-613	-175	-849	-769
Extraordinary income	-	40	-	-
Extraordinary expenses	0	0	9	-264
Income before income taxes and minority interests	-613	-135	-859	-504
Corporation tax, etc.	-201	-59	-263	-97
(Tax burden)				
Minority interests	5	7	4	3
Profit attributable to owners of parent	-418	-82	-600	-410

Third Quarter							
First Half	(Cumulative)	Full-year					
335	219	119					
1,113	1,883	2,795					
-778	-1,664	-2,676					
30	-87	-211					
-809	-1,577	-2,465					
130	120	179					
110	182	121					
-789	-1,638	-2,408					
40	40	40					
0	10	-254					
-749	-1,608	-2,113					
-261	-524	-621					
12	16	20					
-500	-1,101	-1,511					

Change

	First	Second	Third	Fourth
	Quarter	Quarter	Quarter	Quarter
Net sales	102.5	101.1	98.9	98.9
Cost of Sales	113.6	106.3	112.7	116.0
Gross profit	87.9	92.2	79.3	73.0
SG&A expenses	102.7	98.7	95.1	94.3
Operating income	70.1	80.9	59.1	43.4
Other income				
Other expenses				
Ordinary income	66.7	86.7	58.8	46.1
Extraordinary income				
Extraordinary expenses				
Income before income taxes and minority interests		89.7	58.3	47.6
Corporation tax, etc.				
(Tax burden)				
Minority interests				
Profit attributable to owners of parent	67.9	91.1	59.4	32.2

		(%)
	Third Quarter	
First Half	(Cumulative)	Full-year
101.7	100.7	100.3
109.7	110.7	112.0
89.9	86.1	83.0
100.7	98.7	97.7
74.6	68.9	62.8
		1
75.0	68.6	63.8
76.3	69.2	65.9
77.6	70.3	65.0

Breakdown

	First	Second	Third	Fourth
	Quarter	Quarter	Quarter	Quarter
Net sales	100.0	100.0	100.0	100.0
Cost of Sales	62.9	66.1	66.8	70.8
Gross profit	37.1	33.9	33.2	29.2
SG&A expenses	23.7	23.0	22.3	21.9
Operating income	13.5	10.9	10.9	7.3
Other income				
Other expenses				
Ordinary income	12.7	11.6	11.9	7.0
Extraordinary income				
Extraordinary expenses				
Income before income taxes and minority interests	12.7	12.0	11.8	4.9
Corporation tax, etc.				
(Tax burden)				
Minority interests				
Profit attributable to owners of parent	9.2	8.6	8.6	2.1

		(%
	Third Quarter	
First Half	(Cumulative)	Full-year
100.0	100.0	100.0
64.5	65.3	66.6
35.5	34.7	33.4
23.4	23.0	22.7
12.2	11.7	10.7
12.1	12.1	10.9
12.4	12.2	10.4
8.9	8.8	7.2
		•

Fiscal 2024 Projected Statements of Income

Cumulative

¥ millions, rounded down,(%)

	First Half	% of total	Full-year	% of total			
Net sales	20,110	100.0	40,850	100.0			
Operating income	1,940	9.6	4,690	11.5			
Ordinary income	2,030	10.1	4,800	11.8			
Profit attributable to owners of parent	1,440	7.2	3,310	8.1			
EPS (before deducting treasury shares)	¥57.01		¥131.05				
EPS (minus treasury shares)	¥59.32		¥136.36				
	Number of sha	ares outstanding	25,256,963				
Shares	s outstanding at F	Y2023 year-end	24,274,142				
Fiscal 2022 Results	l 2022 Results (deducting treasury shares)						
Net sales	19,536	100.0	39,100	100.0			
Operating income	2,375	12.2	4,169	10.7			
Ordinary income	2,373	12.1	4,245	10.9			
Profit attributable to owners of parent	1,732	8.9	2,804	7.2			
Change (Amount and %)							
Net sales	573	102.9	1,749	104.5			
Operating income	-435	81.7	520	112.5			
Ordinary income	-343	85.5	554	113.1			
Profit attributable to owners of parent	-292	83.1	505	118.0			

Fiscal 2023 Sales by Product Grouping

First Half Results

¥ millions, rounded down

	Sept. 2023		Sept.	2022	Year-on-Year		
	Interim	Results	Interim	Results	Comparison		
	Amount	% of total	Amount	% of total	Amount	%	
Sterilization products	1,673	8.6	1,768	9.2	-95	94.6	
Surgical products	17,394	89.0	16,967	88.4	426	102.5	
Treatment products	86	0.4	93	0.5	-7	92.4	
Others	381	2.0	371	1.9	10	102.9	
Total	19,536	100.0	19,201	100.0	335	101.7	
Itemized surgical products							
Non-woven products	3,793	19.4	4,092	21.3	-299	92.7	
Other non-woven products	788	4.0	987	5.1	-199	79.8	
Kit products	12,701	65.0	11,773	61.3	927	107.9	
New products	112	0.6	113	0.6	-1	98.8	
Itemized external sales by subsidi	ary						
Non-woven products	235		257		-22		
Other non-woven products	-		-		-		
Kit products	24		0		23		
Others	34		41		-7		

Third Quarter

¥ millions, rounded down


	Dec. 2023		Dec.	2022	Year-on-Year		
	Interim	Results	Interim	Results	Comparison		
	Amount	% of total	Amount	% of total	Amount	%	
Sterilization products	2,579	8.7	2,661	9.0	-81	96.9	
Surgical products	26,459	88.9	26,160	88.6	298	101.1	
Treatment products	131	0.4	144	0.5	-12	91.5	
Others	583	2.0	569	1.9	14	102.5	
Total	29,754	100.0	29,535	100.0	219	100.7	
Itemized surgical products							
Non-woven products	5,757	19.3	6,161	20.9	-403	93.4	
Other non-woven products	1,146	3.9	1,648	5.6	-502	69.5	
Kit products	19,374	65.1	18,156	61.5	1,218	106.7	
New products	181	0.6	194	0.7	-13	93.1	
Itemized external sales by subsidiary							
Non-woven products	368		405		-36		
Other non-woven products	1		-		1		
Kit products	47		8		38		
Others	55		66		-11		


Full-year


¥ millions, rounded down

	Fisca	2023	Fisca	2022	Year-o	n-Year	Fiscal	2023	Revise	d Plan
	Res	sults	Res	Results Comparison		Revised Plan		Comparison		
	Amount	% of total	Amount	% of total	Amount	%	Amount	% of total	Amount	%
Sterilization products	3,439	8.8	3,487	8.9	-47	98.6	3,414	8.7	25	100.7
Surgical products	34,725	88.8	34,554	88.6	171	100.5	34,879	89.0	-153	99.6
Treatment products	173	0.4	192	0.5	-18	90.4	176	0.5	-3	98.3
Others	761	1.9	747	1.9	14	101.9	729	1.9	31	104.4
Total	39,100	100.0	38,981	100.0	119	100.3	39,200	100.0	-99	99.7
Itemized surgical products	-									
Non-woven products	7,452	19.1	8,014	20.6	-561	93.0	7,450	19.0	2	100.0
Other non-woven products	1,503	3.8	2,109	5.4	-606	71.3	1,485	3.8	17	101.2
Kit products	25,503	65.2	24,164	62.0	1,338	105.5	25,700	65.6	-197	99.2
New products	266	0.7	265	0.7	0	100.3	243	0.6	23	109.5
Itemized external sales by subsidi	iary									
Non-woven products	443		501		-57		446		-2	
Other non-woven products	1		-		1		1		-0	
Kit products	55		47		8		55		-	
Others	66		76		-10		66		0	

Sales Composition by Kit Treatment Category







Fiscal 2024 Sales Plan by Product Line

Sterilization products Surgical products Treatment products Others Total Itemized surgical products Non-woven products Kit products New products Itemized external sales by subsid Non-woven products Other non-woven products Other non-woven products Other non-woven products Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	215 0 32 35	7,134 1,429 27,438 434 415 1 64 70 aunded down Full-year 2 1,710	(Fiscal 2023 Results) Sterilization products Surgical products Treatment products Others Total Itemized surgical products Non-woven products Other non-woven products Kit products New products Itemized external sales by subsidiary Non-woven products Other non-woven products Other non-woven products Other non-woven products Kit products Other non-woven products Kit products Others (Change) Sterilization products	First Half 1,673 17,394 86 381 19,536 3,793 788 12,701 112 235 - 24 34 First Half 100.9	761 39,100 7,452 1,503 25,503 266 443 1 55
Surgical products Treatment products Others Total Itemized surgical products Non-woven products Other non-woven products Kit products New products Itemized external sales by subsid Non-woven products Other non-woven products Kit products Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	17,951 104 366 20,110 3,578 718 13,437 217 liary 215 0 32 35 ¥ millions, ro First Half 15 556	36,436 212 760 40,850 7,134 1,429 27,438 434 415 1 64 70 bunded down Full-year 2 1,710	Surgical products Treatment products Others Total Itemized surgical products Non-woven products Other non-woven products Kit products New products Itemized external sales by subsidiary Non-woven products Other non-woven products Other solutions Other non-woven products Kit products Others (Change)	17,394 86 381 19,536 3,793 788 12,701 112 235 - 24 34	34,725 173 761 39,100 7,452 1,503 25,503 266 443 1 55 66 (%)
Treatment products Others Total Itemized surgical products Non-woven products Other non-woven products Kit products New products Itemized external sales by subsid Non-woven products Other non-woven products Kit products Other non-woven products Change(Amount)) Sterilization products Surgical products Treatment products	104 366 20,110 3,578 718 13,437 217 liary 215 0 32 35 ¥ millions, ro First Half 15 556	212 760 40,850 7,134 1,429 27,438 434 415 1 64 70 bunded down Full-year 2 1,710	Treatment products Others Total Itemized surgical products Non-woven products Other non-woven products Kit products New products Itemized external sales by subsidiary Non-woven products Other non-woven products Kit products Other solutions Others (Change)	86 381 19,536 3,793 788 12,701 112 235 - 24 34	173 761 39,100 7,452 1,503 25,503 266 443 1 55 66 (%) Full-year
Others Total Itemized surgical products Non-woven products Other non-woven products Kit products New products Itemized external sales by subsid Non-woven products Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	366 20,110 3,578 718 13,437 217 liary 215 0 32 35 ¥ millions, refirst Half 15 556	760 40,850 7,134 1,429 27,438 434 415 1 64 70 bunded down Full-year 2 1,710	Others Total Itemized surgical products Non-woven products Other non-woven products Kit products New products Itemized external sales by subsidiary Non-woven products Other non-woven products Kit products Other s (Change)	381 19,536 3,793 788 12,701 112 235 - 24 34	39,100 7,452 1,503 25,503 266 443 1 55 66 (%)
Total Itemized surgical products Non-woven products Other non-woven products Kit products New products Itemized external sales by subsid Non-woven products Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	20,110 3,578 718 13,437 217 liary 215 0 32 35 ¥ millions, ro First Half 15 556	40,850 7,134 1,429 27,438 434 415 1 64 70 bunded down Full-year 2 1,710	Total Itemized surgical products Non-woven products Other non-woven products Kit products New products Itemized external sales by subsidiary Non-woven products Other non-woven products Kit products Others (Change)	19,536 3,793 788 12,701 112 235 - 24 34 First Half	1,503 25,503 266 443 1 55 66 (%)
Itemized surgical products Non-woven products Other non-woven products Kit products New products Itemized external sales by subsid Non-woven products Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	3,578 718 13,437 217 liary 215 0 32 35 ¥ millions, ro First Half 15 556	7,134 1,429 27,438 434 415 1 64 70 bunded down Full-year 2 1,710	Itemized surgical products Non-woven products Other non-woven products Kit products New products Itemized external sales by subsidiary Non-woven products Other non-woven products Kit products Others (Change)	3,793 788 12,701 112 235 - 24 34	7,452 1,503 25,503 266 443 1 55 66 (%)
Non-woven products Other non-woven products Kit products New products Itemized external sales by subsid Non-woven products Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	718 13,437 217 liary 215 0 32 35 ¥ millions, ro First Half 15 556	1,429 27,438 434 415 1 64 70 bunded down Full-year 2 1,710	Non-woven products Other non-woven products Kit products New products Itemized external sales by subsidiary Non-woven products Other non-woven products Kit products Others (Change)	788 12,701 112 235 - 24 34	1,503 25,503 266 443 1 55 66 (%)
Other non-woven products Kit products New products Itemized external sales by subsid Non-woven products Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	718 13,437 217 liary 215 0 32 35 ¥ millions, ro First Half 15 556	1,429 27,438 434 415 1 64 70 bunded down Full-year 2 1,710	Other non-woven products Kit products New products Itemized external sales by subsidiary Non-woven products Other non-woven products Kit products Others (Change)	788 12,701 112 235 - 24 34	1 55 66 (%) Full-year
Kit products New products Itemized external sales by subsid Non-woven products Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	13,437 217 liary 215 0 32 35 ¥ millions, ro First Half 15 556	27,438 434 415 1 64 70 bunded down Full-year 2 1,710	Kit products New products Itemized external sales by subsidiary Non-woven products Other non-woven products Kit products Others (Change)	12,701 112 235 - 24 34	25,503 266 443 1 55 66 (%)
New products Itemized external sales by subsid Non-woven products Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	217 215 0 32 35 ¥ millions, ro First Half 15 556	434 415 1 64 70 bunded down Full-year 2 1,710	New products Itemized external sales by subsidiary Non-woven products Other non-woven products Kit products Others (Change)	235 - 24 34	266 443 1 55 66 (%)
Itemized external sales by subsid Non-woven products Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	215 0 32 35 ¥ millions, ro First Half 15 556	415 1 64 70 bunded down Full-year 2 1,710	Itemized external sales by subsidiary Non-woven products Other non-woven products Kit products Others (Change)	235 - 24 34 First Half	443 1 55 66 (%) Full-year
Non-woven products Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	215 0 32 35 ¥ millions, ro First Half 15 556	1 64 70 bunded down Full-year 2 1,710	Non-woven products Other non-woven products Kit products Others (Change)	- 24 34 First Half	1 55 66 (%) Full-year
Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	0 32 35 ¥ millions, ro First Half 15 556	1 64 70 bunded down Full-year 2 1,710	Other non-woven products Kit products Others (Change)	- 24 34 First Half	55 66 (%) Full-year
Other non-woven products Kit products Others (Change(Amount)) Sterilization products Surgical products Treatment products	0 32 35 ¥ millions, ro First Half 15 556	64 70 bunded down Full-year 2 1,710	Kit products Others (Change)	34 First Half	
(Change(Amount)) Sterilization products Surgical products Treatment products	¥ millions, ro First Half 15 556	50 punded down Full-year 2 1,710	Kit products Others (Change)	34 First Half	66 (%) Full-year
(Change(Amount)) Sterilization products Surgical products Treatment products	¥ millions, ro First Half 15 556	50 punded down Full-year 2 1,710	Others (Change)	First Half	66 (%) Full-year
Sterilization products Surgical products Treatment products	First Half 15 556	Full-year 2 1,710			Full-year
Sterilization products Surgical products Treatment products	15 556	2 1,710			
Surgical products Treatment products	556		Sterilization products	100.9	100.1
Treatment products					
	171		Surgical products	103.2	104.9
Others	-15	38 -1	Treatment products Others	120.0 95.8	122.0 99.8
Total	573	1,749	Total	102.9	104.5
Itemized surgical products	3.3	-// 13	Itemized surgical products	102.0	10.10
Non-woven products	-215	-318	Non-woven products	94.3	95.7
Other non-woven products	-70	-73	Other non-woven products	91.1	95.1
Kit products	736	1,935	Kit products	105.8	107.6
New products	104	167	New products	193.6	162.8
Itemized external sales by subsidiary			Itemized external sales by subsidiary		
Non-woven products	-20	-28	Non-woven products	91.2	93.5
Other non-woven products	0	0	Other non-woven products	-	128.9
Kit products	7	8	Kit products	132.8	114.4
Others	0	3	Others	101.9	105.4
(Breakdown)	First Half	(%) Full-year			
Sterilization products	8.4	8.4			
Surgical products	89.3	89.2			
Treatment products	0.5	0.5			
Others	1.8	1.9			
Total	100.0	100.0			
Itemized surgical products	17.0	17.5			
Non-woven products Other non-woven products	17.8 3.6	17.5 3.5			
Kit products	66.8	5.5 67.2			
New products	1.1	1.1			
Itemized external sales by subsidiary					
Non-woven products	1.1	1.0			
Other non-woven products	0.0	0.0			
Kit products Others	0.2 0.2	0.2 0.2			

SG&A and Other Income/Expenses (Actual and Forecast, Consolidated)

SG&A Expenses

¥ millions, rounded down

	Fiscal 2023	Fiscal 2022	Year-on-Year	Fiscal 2023	Year-on-Year
	Results	Results	Comparison	Plan	Comparison
Packaging and transportation	1,089	1,120	-31	1,161	72
Losses on doubtful accounts	-	-	-	-	-
Samples	375	287	87	401	26
Advertising	61	62	△0	65	3
Personnel	4,008	4,014	-6	4,041	32
Travel	437	454	-17	462	25
Communication	142	147	-4	144	1
Consumables	47	51	-4	63	15
Taxes and public charges	312	333	-20	305	-6
Depreciation	572	669	-96	557	-15
Testing and research	220	353	-133	394	173
Land and housing rent	438	437	0	441	3
Miscellaneous	544	497	47	543	-1
Others	643	677	-33	797	153
Total	8,894	9,105	-211	9,380	485

Other Income/Expenses

¥ millions, rounded down

	Fiscal 2023	Fiscal 2022	Year-on-Year	Fiscal 2023	Year-on-Year
	Results	Results	Comparison	Plan	Comparison
Interest received	249	106	143	160	-89
Interest on negotiable securities	-	0	-0	-	-
Dividend received	58	49	8	50	-8
(Total financial earnings)	307	156	151	210	-97
Foreign exchange gain	-	0	-0	-	-
Miscellaneous income	132	104	27	50	-82
Total Other income	440	261	179	260	-180
Paid interest	23	29	-6	30	6
(Total financial expenses)	23	29	-6	30	6
Foreign exchange loss	37	0	37	-	-37
Miscellaneous losses	303	212	90	120	-183
Total non-operating expenses	363	242	121	150	-213

Capital Expenditures and Depreciation Expenses (Actual and Forecast, Consolidated)

Capital Expenditures

¥ millions, rounded down,(%)

Total Depreciation

Expenses

96.4

94.5 124.7

130.6

141.4 90.3

93.8

86.1

90.5 88.3

181.8

87.2

Capital Expe	enditures	Depreciation Expenses ¥ millions, r						
	Capital Expenditures	Year-on-Year Comparison		SG&A Expenses	Year-on-Year Comparison	Manufacturing Costs	Year-on-Year Comparison	Total Depreciation Expenses
Fiscal 2012	1,915	117.0	Fiscal 2012	844	116.6	2,127	90.9	2,971
Fiscal 2013	7,174	374.6	Fiscal 2013	922	109.2	1,942	91.3	2,865
Fiscal 2014	15,082	210.2	Fiscal 2014	951	103.1	1,757	90.5	2,708
Fiscal 2015	9,080	60.2	Fiscal 2015	1,044	109.8	2,331	132.7	3,376
Fiscal 2016	6,649	73.2	Fiscal 2016	1,007	96.5	3,402	145.9	4,409
Fiscal 2017	2,142	32.2	Fiscal 2017	914	90.8	5,320	156.4	6,235
Fiscal 2018	3,364	157.0	Fiscal 2018	998	109.2	4,632	87.1	5,631
Fiscal 2019	10,904	324.1	Fiscal 2019	1,070	107.2	4,212	90.9	5,283
Fiscal 2020	5,261	48.2	Fiscal 2020	906	84.7	3,643	86.5	4,549
Fiscal 2021	3,489	66.3	Fiscal 2021	805	88.9	3,309	90.8	4,115
Fiscal 2022	1,458	41.8	Fiscal 2022	669	83.1	2,966	89.6	3,635
Fiscal 2023	1,249	85.7	Fiscal 2023	572	85.5	6,034	203.4	6,607
Fiscal 2024	5,270	421.9	Fiscal 2024	540	94.4	5,220	86.5	5,760
Note: Figures for	Fiscal 2024 are Compa	ny forecasts.	n-	Depreciation at P.T. H	IOGY INDONESIA is in	cluded in manufacturin	g costs.	•

Fiscal 2005 Operamaster expansion line : 1,469, New distribution center : 1,947

Fiscal 2006 New distribution center : 886

Fiscal 2007 Industrial-use land : 973
Fiscal 2008 Industrial-use land : 752, Sterilization equipment : 876 ,Indonesia factory : 381

Fiscal 2009 Sterilization equipment: 1,833 ,Indonesia factory: 995

Fiscal 2010 Sterilization equipment: 2,732 Fiscal 2013 New plant construction costs : 5,166

Fiscal 2014 New plant construction costs : 8,113. New plant equipment costs : 4,567

Fiscal 2015 New plant: 7,300 Fiscal 2016 New plant : 5,981

Fiscal 2019 New plant additional investment : 9,512 Fiscal 2020 New plant additional investment : 3,644 Fiscal 2021 New plant additional investment : 1,830 $\,$

Balance Sheets (Major Changes)/Statements of Cash Flows (Consolidated)

Major Changes on Balance Sheets

¥ millions, rounded down

	Balance at	Change		Balance at	Change
	March. 31,			March. 31,	
Current assets	43,025	2,735	Current liabilities	8,241	-2,893
Cash and bank deposits	19,419	557	Notes and accounts payable	4,834	21
Notes and accounts receivable	12,766	804	Accrued expenses	131	-218
Short-term investments	-	-	Long-term loans due within 1 year	1,999	-
Inventories	9,457	589	Income taxes	102	-1,111
Others	1,382	784	Allowance for employees' bonuses	534	25
			Payable notes for equipment	155	-1,068
			Reserve for disaster loss	-	-
			Others	482	-542
Fixed assets	57,015	-4,874	Long-term liabilities	5,680	-1,687
Property, plant and equipment	45,712	-5,843	Long-term borrowings	3,669	-1,999
Buildings and structures	19,534	-1,175	Others	2,011	311
Machinery, equipment and vehicles	14,726	9,889	Total liabilities	13,921	-4,580
Land	9,728	32	Total net assets	86,120	2,441
Construction in progress	1,241	-14,488	Common stock	7,123	-
Others	481	-101	Capital surplus	8,294	23
Intangibles	495	-324	Retained earnings	67,762	-23,379
Investments and others	10,807	1,293	Treasury stock	-3,217	24,344
Investments securities	9,213	974	Others	6,157	1,453
Others	1,594	319			
Total assets	100,041	-2,139	Total liabilities and shareholders' equity	100,041	-2,139

^{*}Comparison with end of previous fiscal year:

Equity ratio increased from 81.8% at the end of the previous fiscal year to 86.1%.

Statements of Cash Flows

¥ millions, rounded down

Statements of cash flows		1 111111	ons, rounded down
I Operating activities	7,117	Income before income taxes	4,075
		Depreciation	6,607
		Incomes taxes paid	-2,252
II Investing activities	-3,262	Purchase of tangible fixed assets	-2,686
III Financing activities	-3,892	Repayment of long-term borrowings	-1,999
		Cash dividends paid	-1,892
IV Effect of exchange rate changes	310		
Net changes in cash and cash equivalents	272		

First Quarter

¥ millions, rounded down

		June 2 Resu		June 2022 Results		Year-on-Year Comparison	
		Amount	% of total	Amount	% of total	Amount	%
Net sales		9,564	100.0	9,316	100.0	248	102.7
Cost of Sales		6,132	64.1	5,424	58.2	708	113.1
	Gross profit	3,431	35.9	3,891	41.8	-460	88.2
SG&A expenses		2,232	23.3	2,162	23.2	70	103.2
	Operating income	1,198	12.5	1,729	18.6	-530	69.3
Other income		65		28		36	
Other expenses		199		55		143	
	Ordinary income	1,064	11.1	1,702	18.3	-637	62.6
Extraordinary income		-		-		-	
Extraordinary expenses		0		0		0	
	Income before income taxes	1,064	11.1	1,702	18.3	-637	62.5
	Corporation tax, etc.	320		514		-193	
	(Tax burden)	30.1%		30.2%			
	Net income	743	7.8	1,187	12.7	-443	62.6
EDS (total charge)		¥29.45		¥36 34			

 EPS (total shares)
 # 29-45
 # 30-34

 EPS (minus treasury shares)
 # 30.67
 # 48.96

 Number of shares outstanding
 25,256,963
 32,682,310

 treasury shares)
 24,256,963
 24,257,102

First Half Results

¥ millions, rounded down

	-	Sept. 2023 Interim Results		Sept. 2022 Interim Results		-Year rison
	Amount	% of total	Amount	% of total	Amount	%
Net sales	19,263	100.0	18,910	100.0	352	101.9
Cost of Sales	12,678	65.8	11,447	60.5	1,231	110.8
Gross profit	t 6,585	34.2	7,463	39.5	-878	88.2
SG&A expenses	4,428	23.0	4,377	23.1	51	101.2
Operating income	2,156	11.2	3,086	16.3	-930	69.9
Other income	146		100		45	
Other expenses	272		166		106	
Ordinary income	2,030	10.5	3,021	16.0	-991	67.2
Extraordinary income	40		-		40	
Extraordinary expenses	0		0		0	
Income before income taxes	2,070	10.7	3,021	16.0	-951	68.5
Corporation tax, etc	. 623		913		-289	
(Tax burden	30.1%		30.2%			
Net income	1,446	7.5	2,108	11.1	-661	68.6

Third Quarter

¥ millions, rounded down

		Dec. 2023 Interim Results		Dec. 2022 Interim Results		Year-on-Year Comparison	
		Amount	% of total	Amount	% of total	Amount	%
Net sales		29,309	100.0	29,086	100.0	222	100.8
Cost of Sales		19,592	66.8	17,631	60.6	1,961	111.1
	Gross profit	9,716	33.2	11,455	39.4	-1,738	84.8
SG&A expenses		6,632	22.6	6,706	23.1	-74	98.9
	Operating income	3,084	10.5	4,748	16.3	-1,664	64.9
Other income		208		195		13	
Other expenses		323		126		196	
	Ordinary income	2,969	10.1	4,817	16.6	-1,847	61.6
Extraordinary income		40		-		40	
Extraordinary expenses		0		0		0	
	Income before income taxes	3,009	10.3	4,817	16.6	-1,807	62.5
	Corporation tax, etc.	906		1,455		-549	
	(Tax burden)	30.1%		30.2%			
	Net income	2,103	7.2	3,361	11.6	-1,258	62.6
EPS (total shares)		¥83.28		¥102.85			

 EPS (total shares)
 ¥83.28
 ¥102.85

 EPS (minus treasury shares)
 ¥86.68
 ¥138.57

 Number of shares outstanding
 25,256,963
 32,682,310

 treasury shares)
 24,266,016
 24,257,041

Full-year

¥ millions, rounded down

	Fiscal 2023 Results		Fiscal 2022 Results		Year-on-Year Comparison		Fiscal 2023 Revised Plan		Revised Plan Comparison	
	Amount	% of total	Amount	% of total	Amount	%	Amount	% of tota	Amount	%
Net sales	38,569	100.0	38,389	100.0	179	100.5	38,657	100.0	-87	99.8
Cost of Sales	26,270	68.1	23,446	61.1	2,823	112.0	26,310	68.1	-39	99.9
Gross profit	12,298	31.9	14,942	38.9	-2,644	82.3	12,347	31.9	-48	99.6
SG&A expenses	8,621	22.4	8,826	23.0	-204	97.7	8,810	22.8	-188	97.9
Operating income	3,676	9.5	6,116	15.9	-2,439	60.1	3,537	9.1	139	104.0
Other income	533		452		80		520		13	
Other expenses	439		298		140		490		-50	
Ordinary income	3,771	9.8	6,270	16.3	-2,498	60.1	3,567	9.2	204	105.7
Extraordinary income	40		-		40		40		0	
Extraordinary expenses	770		464		306		190		580	
Income before income taxes	3,041	7.9	5,805	15.1	-2,764	52.4	3,417	8.8	-375	89.0
Corporation tax, etc.	943		1,743		-799		1,037		-93	
(Tax burden)	31.0%		30.0%				30.3%			
Net income	2,097	5.4	4,062	10.6	-1,964	51.6	2,380	6.2	-282	88.1
EPS (total shares)	¥83.06		¥124.30				¥94.23			

 EPS (total shares)
 ¥83.06
 ¥124.30
 ¥94.23

 EPS (minus treasury shares)
 ¥86.44
 ¥167.48
 ¥98.07

 Number of shares outstanding
 25,256,963
 32,682,310
 25,256,963

 treasury shares)
 24,268,040
 24,257,024
 24,268,040

Fiscal 2023 Results

¥ millions, rounded down

riscai 2023 Results				
	First	Second	Third	Fourth
	Quarter	Quarter	Quarter	Quarter
Net sales	9,564	9,699	10,045	9,260
Cost of Sales	6,132	6,545	6,914	6,678
Gross profit	3,431	3,154	3,131	2,582
SG&A expenses	2,232	2,195	2,203	1,989
Operating income	1,198	958	927	592
Other income	65	81	62	324
Other expenses	199	73	50	116
Ordinary income	1,064	965	939	801
Extraordinary income	-	40	-	-
Extraordinary expenses	0	0	0	769
Income before income taxes	1,064	1,005	939	31
Corporation tax, etc.	320	302	282	37
(Tax burden)	30.1%	30.1%	30.1%	117.7%
Net income	743	702	656	-5

¥ millions, rounded dow							
	Third Quarter						
First Half	(Cumulative)	Full-year					
19,263	29,309	38,569					
12,678	19,592	26,270					
6,585	9,716	12,298					
4,428	6,632	8,621					
2,156	3,084	3,676					
146	208	533					
272	323	439					
2,030	2,969	3,771					
40	40	40					
0	0	770					
2,070	3,009	3,041					
623	906	943					
30.1%	30.1%	31.0%					
1,446	2,103	2,097					

Fiscal 2022 Results

¥ millions, rounded down

	First	Second	Third	Fourth
	Quarter	Quarter	Quarter	Quarter
Net sales	9,316	9,594	10,175	9,303
Cost of Sales	5,424	6,022	6,184	5,815
Gross profit	3,891	3,571	3,991	3,487
SG&A expenses	2,162	2,214	2,329	2,119
Operating income	1,729	1,357	1,661	1,367
Other income	28	72	95	256
Other expenses	55	110	-39	171
Ordinary income	1,702	1,319	1,796	1,452
Extraordinary income	-	-	-	-
Extraordinary expenses	0	0	0	464
Income before income taxes	1,702	1,319	1,795	988
Corporation tax, etc.	514	398	542	287
(Tax burden)	30.2%	30.2%	30.2%	29.1%
Net income	1,187	920	1,253	701

	Third Quarter	
	-	
First Half	(Cumulative)	Full-year
18,910	29,086	38,389
11,447	17,631	23,446
7,463	11,455	14,942
4,377	6,706	8,826
3,086	4,748	6,116
100	195	452
166	126	298
3,021	4,817	6,270
-	-	-
0	0	464
3,021	4,817	5,805
913	1,455	1,743
30.2%	30.2%	30.0%
2,108	3,361	4,062

Change(Amount)

¥ millions, rounded down

	First	Second	Third	Fourth
	Quarter	Quarter	Quarter	Quarter
Net sales	248	104	-129	-43
Cost of Sales	708	522	730	862
Gross profit	-460	-417	-860	-905
SG&A expenses	70	-18	-125	-130
Operating income	-530	-399	-734	-775
Other income	36	9	-32	67
Other expenses	143	-36	89	-55
Ordinary income	-637	-353	-856	-651
Extraordinary income	-	40	-	-
Extraordinary expenses	0	0	-0	305
Income before income taxes	-637	-313	-856	-957
Corporation tax, etc.	-193	-95	-259	-250
(Tax burden)				
Net income	-443	-217	-596	-706

Third Quarter									
	-								
First Half	(Cumulative)	Full-year							
352	222	179							
1,231	1,961	2,823							
-878	-1,738	-2,644							
51	-74	-204							
-930	-1,664	-2,439							
45	13	80							
106	196	140							
-991	-1,847	-2,498							
40	40	40							
0	0	306							
-951	-1,807	-2,764							
-289	-549	-799							
-661	-1,258	-1,964							

Change

(%)

	First	Second	Third	Fourth
	Quarter	Quarter	Quarter	Quarter
Net sales	102.7	101.1	98.7	99.5
Cost of Sales	113.1	108.7	111.8	114.8
Gross profit	88.2	88.3	78.5	74.0
SG&A expenses	103.2	99.2	94.6	93.8
Operating income	69.3	70.6	55.8	43.3
Other income				
Other expenses				
Ordinary income	62.6	73.2	52.3	55.2
Extraordinary income				
Extraordinary expenses				
Income before income taxes	62.5	76.2	52.3	3.2
Corporation tax, etc.				
(Tax burden)				-
Net income	62.6	76.4	52.4	-0.8

	Third Quarter	
First Half	(Cumulative)	Full-year
101.9	100.8	100.5
110.8	111.1	112.0
88.2	84.8	82.3
101.2	98.9	97.7
69.9	64.9	60.1
67.2	61.6	60.1
68.5	62.5	52.4
68.6	62.6	51.6

Breakdown

(%)

	First	Second	Third	Fourth
	Quarter	Quarter	Quarter	Quarter
Net sales	100.0	100.0	100.0	100.0
Cost of Sales	64.1	67.5	68.8	72.1
Gross profit	35.9	32.5	31.2	27.9
SG&A expenses	23.3	22.6	21.9	21.5
Operating income	12.5	9.9	9.2	6.4
Other income				
Other expenses				
Ordinary income	11.1	10.0	9.4	8.7
Extraordinary income				
Extraordinary expenses				
Income before income taxes	11.1	10.4	9.4	0.3
Corporation tax, etc.				
(Tax burden)				
Net income	7.8	7.2	6.5	-0.1

		(%)
	Third Quarter	
First Half	(Cumulative)	Full-year
100.0	100.0	100.0
65.8	66.8	68.1
34.2	33.2	31.9
23.0	22.6	22.4
11.2	10.5	9.5
10.5	10.1	9.8
10.7	10.3	7.9
7.5	7.2	5.4

Fiscal 2024 Projected Statements of Income (Non-Consolidated)

Cumulative

¥ millions, rounded down,(%)

			1 millions, rounded down, 70			
	First Half	% of total	Full-year	% of total		
Net sales	19,851	100.0	40,350	100.0		
Operating income	1,721	8.7	4,060	10.1		
Ordinary income	1,711	8.6	4,310	10.7		
Net income	1,201	6.1	3,020	7.5		
EPS (before deducting treasury share	¥47.55		¥119.57			
EPS (minus treasury shares)	¥49.48		¥124.41			
	Number of sh	ares outstanding	25,256,963			
Shares	outstanding at F	Y2023 year-end	24,274,142			
Fiscal 2022 Results	(deducting	treasury shares)				
Net sales	19,263	100.0	38,569	100.0		
Operating income	2,156	11.2	3,676	9.5		
Ordinary income	2,030	10.5	3,771	9.8		
Net income	1,446	7.5	2,097	5.4		
Change (Amount and %)						
Net sales	587	103.0	1,780	104.6		
Operating income	-435	79.8	383	110.4		
Ordinary income	-319	84.3	538	114.3		
Net income	-245	83.0	922	144.0		

Total Manufacturing Costs (Non-Consolidated)

¥ millions, rounded down

=										-	
	FY2014	FY2015	FY2016	FY2017	FY 2018	FY2019	FY2020	FY2021	FY2022	FY2023	Plan FY2024
Materials	11,728	12,545	12,945	12,803	12,769	12,765	12,883	12,287	13,870	15,030	15,876
Personnel	1,797	1,795	1,742	1,713	1,661	1,658	1,750	1,748	1,853	1,958	1,970
Outsourcing	389	406	411	398	412	369	390	367	406	425	439
Depreciation expenses	1,370	1,969	3,081	5,035	4,392	3,974	3,385	3,030	2,627	5,679	4,808
Others	1,492	1,466	1,755	1,910	2,209	2,139	2,116	2,275	2,456	2,387	2,465
Total	16,779	18,183	19,935	21,861	21,445	20,907	20,527	19,709	21,215	25,482	25,559

Increase Rate

	FY2014	FY2015	FY2016	FY2017	FY 2018	FY2019	FY2020	FY2021	FY2022	FY2023	Plan FY2024
Materials	108.4	107.0	103.2	98.9	99.7	100.0	100.9	95.4	112.9	108.4	105.6
Personnel	95.5	99.9	97.1	98.3	97.0	99.8	105.6	99.8	106.0	105.7	100.6
Outsourcing	93.9	104.4	101.1	96.9	103.4	89.6	105.8	94.1	110.6	104.9	103.2
Depreciation expenses	85.5	143.7	156.4	163.4	87.2	90.5	85.2	89.5	86.7	216.1	84.7
Others	98.7	98.2	119.7	108.9	115.6	96.8	98.9	107.5	107.9	97.2	103.3
Total	103.4	108.4	109.6	109.7	98.1	97.5	98.2	96.0	107.6	120.1	100.3

Composition Rate

	FY2014	FY2015	FY2016	FY2017	FY 2018	FY2019	FY2020	FY2021	FY2022	FY2023	Plan FY2024
Materials	69.9	69.0	64.9	58.6	59.5	61.1	62.8	62.3	65.4	59.0	62.1
Personnel	10.7	9.9	8.7	7.8	7.7	7.9	8.5	8.9	8.7	7.7	7.7
Outsourcing	2.3	2.2	2.1	1.8	1.9	1.8	1.9	1.9	1.9	1.7	1.7
Depreciation expenses	8.2	10.8	15.5	23.0	20.5	19.0	16.5	15.4	12.4	22.3	18.8
Others	8.9	8.1	8.8	8.7	10.3	10.2	10.3	11.5	11.6	9.4	9.6
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

